FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Scheer David (Last) (First) (Middle) C/O ACHILLION PHARMACEUTICALS, INC.					ACI [AC	Issuer Name and Ticker or Trading Symbol ACHILLION PHARMACEUTICALS INC [ACHN] Date of Earliest Transaction (Month/Day/Year) 12/14/2018								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) below)					
300 GEORGE STREET (Street) NEW HAVEN CT 06511 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year) ative Securities Acquired, Disposed of, or Benefi								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Y			ion 2 l	n 2A. Deemed Execution Date,			3. Transac Code (Ir 8)	tion	4. Securities Acquired (AD Disposed Of (D) (Instr. 3 and 5)			or 5. Amount of			: Direct I r E ect (I) ('. Nature of ndirect Beneficial Ownership Instr. 4)			
								Code	v	Amount	(A) o (D)	Price	Reporte Transac (Instr. 3	d tion(s)			,		
Common Stock 12/14/20				018	18			M		20,000 A		\$1.0	5 20,	20,000		D			
Common Stock											63,249			1 1 "	See cootnote ⁽¹⁾				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Ex Security or Exercise (Month/Day/Year) if				emed ion Date, //Day/Year)		Transaction Code (Instr.		umber ivative urities urited or posed D) tr. 3, 4 5)	6. Date Exercisal Expiration Date (Month/Day/Year		Amount of Securities Underlying Derivative Security (Instant)		of s ng e (Instr. 3	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Followin Reported Transacti (Instr. 4)	e s illy g	10. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares						
Employee Stock Option	\$1.05	12/14/2018			М			20,000	(2)	1	2/15/2018	Common Stock	20,000	\$0.00	0		D		

Explanation of Responses:

- 1. Consists of shares held by Scheer Investment Holdings III, LLC. Mr. Scheer is the Managing Member of Scheer Investment Holdings III, LLC. and as such may be deemed to have shared voting and investment power with respect to the shares held by Scheer Investment Holdings III, LLC. Mr. Scheer disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- 2. This option was granted on December 15, 2008 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter.

Remarks:

See Exhibit 24.1, Power of Attorney

/s/ Keri Lantz, attorney in fact 12/18/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Keri Lantz and Martha Manning, signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Achillion Pharmaceuticals, Inc.. (the "Company"), Forms 3, 4, and 5(including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act"); (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; (3) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii)

any obligation or liability of the undersigned for profit disgorgement under

Section 16(b) of the

Exchange Act.

This Power of Attorney shall remain in full force and effect until the under signed

is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and $\,$

transactions in securities issued by the Company, unless earlier revoked by the undersigned in a

signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of December, 2018.

David Scheer_ _____

/s/ David Scheer______Signature if individual

By:/s/ Scheer Investment Holdings III Signature if entity

Title: Managing Member
Print title of person signing
if entity